Skip to main content

Investment Firm Upgrades Affy Stock Despite Disappointing Q1 Results

NEW YORK, April 24 (GenomeWeb News) - Investment firm Global Brown Capital upgraded Affymetrix's stock to "Overweight" from "Underweight" today despite the microarray company's disappointing first-quarter revenue and earnings, announced late last week.

 

The upgrade comes one business day after investment bank Deutsche Securities downgraded the stock to "Hold" from "Buy."

 

As GenomeWeb News reported last week,Affymetrix said that first-quarter sales declined more than 10 percent as overall revenue fell 2.5 percent year over year amid growing R&D expenses and shrunken profits.

 

The results caused shares in the company to fall 19 percent briefly to $27.54, a new 52-week low, though they closed at $29.03. Today the stock was up nearly half a percent, or $.12, at $29.15 in mid-afternoon trading. Affy's stock has lost more than half its value since early July last year.

 

Two days earlier, the company said Sue Siegel, president since 1999,  has resigned.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.